Adults with obesity and metabolic syndrome but without diabetes experienced improvements in inflammatory measures as well as fasting insulin and insulin resistance after taking colchicine twice daily for three months, compared with those on a placebo, according to a study in Diabetes, Obesity and Metabolism. Researchers recruited 40 individuals and found that colchicine users experienced reductions in C-reactive protein, absolute neutrophil count, erythrocyte sedimentation rate and white blood cell count.
Study looks at colchicine for obesity, metabolic syndrome
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.